Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program

被引:5
作者
Hung, Tawny [1 ,2 ]
Wolber, Robert [3 ]
Garratt, John [1 ,2 ]
Kalloger, Steven [1 ,2 ]
Gilks, C. Blake [1 ,2 ]
机构
[1] Vancouver Gen Hosp, Dept Pathol, Vancouver, BC V5Z 1M9, Canada
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] Lions Gate Hosp, N Vancouver, BC, Canada
关键词
ER; PR; HER2; breast biomarkers; quality assurance; proficiency testing; QUALITY-ASSURANCE PROGRAM; IMMUNOHISTOCHEMICAL-DEMONSTRATION; PROGESTERONE-RECEPTORS; ESTROGEN-RECEPTOR; LABORATORIES; RELIABILITY; HER2; IHC;
D O I
10.3109/00313025.2010.520306
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aims: We describe a simple, low cost, high frequency immunohistochemistry external proficiency testing program, and show how its use can lead to improved breast cancer biomarker detection. Methods: Over a 30 month period in British Columbia, Canada, we used tissue microarray slides to follow the performance of twelve clinical laboratories in nine separate external proficiency testing runs. Sensitivity for detection of oestrogen receptor (ER), progesterone receptor (PR), and HER2 were calculated for each laboratory, biomarker, and run. Results: Mean sensitivities for detection of ER, PR, and HER2 were 97.1%, 84.8%, and 90.7%, respectively. HER2 sensitivity improved over time, from 87.0% to 92.9% (p=0.04), with a trend towards improvement seen for PR (81.9-88.1%, p=0.13). ER sensitivities were high throughout the test period. Improvements occurred without mandating any specific laboratory changes. Conclusions: This simple, low cost, high frequency external proficiency testing program is highly sustainable and can be implemented in any multi-institutional group or region.
引用
收藏
页码:637 / 642
页数:6
相关论文
共 17 条
[1]   Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program [J].
Francis, Glenn D. ;
Dimech, Margaret ;
Giles, Leanne ;
Hopkins, Alison .
JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (11) :1277-1283
[2]   Current issues in ER and HER2 testing by IHC in breast cancer [J].
Gown, Allen M. .
MODERN PATHOLOGY, 2008, 21 :S8-S15
[3]   Tweaking and Nudging Toward Improved-IHC Quality [J].
Gown, Allen M. .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2009, 17 (05) :363-365
[4]   Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study [J].
Mohsin, SK ;
Weiss, H ;
Havighurst, T ;
Clark, GM ;
Berardo, M ;
Roarth, L ;
To, TV ;
Zho, Q ;
Love, RR ;
Allred, DC .
MODERN PATHOLOGY, 2004, 17 (12) :1545-1554
[5]  
MURPHY H, 2009, COLL AM PATHOLOGISTS
[6]  
*NAT CANC I CAN CA, 2007, CAN CANC STAT 2007
[7]  
Oyama Tetsunari, 2007, Breast Cancer, V14, P182
[8]  
Parker RL, 2002, AM J CLIN PATHOL, V117, P723
[9]  
*RCPA QAP, 2009, RCP AN PATH AQP
[10]   Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories [J].
Regitnig, P ;
Reiner, A ;
Dinges, HP ;
Höfler, G ;
Müller-Holzner, E ;
Lax, SF ;
Obrist, P ;
Rudas, M ;
Quehenberger, F .
VIRCHOWS ARCHIV, 2002, 441 (04) :328-334